SAN DIEGO - PassPort Technologies, Inc. (PPTI), a pioneer in transdermal drug delivery systems, has announced a research collaboration with Arcturus Therapeutics (NASDAQ: NASDAQ:ARCT), a leader in mRNA medicines and vaccines. This partnership aims to explore the potential of transdermal delivery for mRNA-based vaccines and therapeutics, combining PPTI's innovative PassPort® system with ARCT's mRNA and LUNAR® platform technologies.
The collaboration will focus on adapting Arcturus's select mRNA formulations for integration with the PassPort® technology, which utilizes microporation to create micropores in the skin for drug delivery. This method could offer an alternative to traditional injection and infusion methods for administering biologics and oligonucleotides.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.